OBJECTIVES: To compare quantitative magnetic resonance imaging (MRI) and power Doppler ultrasonography (PDUS) with conventional measures of disease activity in rheumatoid arthritis (RA) patients treated with the anti-interleukin 6 (anti-IL 6) receptor antibody tocilizumab in terms of responsiveness at a few months to disease activity and ability to predict structural damage at 1 year. METHODS: A cohort of patients with RA (n = 29) was evaluated clinically including disease activity score 28 (DAS28) and by semiquantitative (SQ-) and quantitative (Q-) PDUS (bilateral metacarpophalangeal joints) and MRI (one hand and wrist) at initiation of treatment with anti-IL 6 receptor antibody agents and after 2 and 5 months. Conventional radiography for both hands and wrists was performed at baseline and at 12 months. Responsiveness was assessed by standardized response means (SRM). Areas under the curve (AUC) for measures at baseline, 2 and 5 months were correlated with structural damage at 1 year. RESULTS: Among the laboratory and clinical parameters, DAS28-ESR was the most responsive with a large effect size of SRM. Structural damage progressions for radiography and MR erosion were correlated with AUC of MR bone erosion and Q-PDUS, respectively. CONCLUSIONS: In the evaluation of disease activity in RA patients in the first few months after starting anti-IL 6 receptor antibody tocilizumab treatment, the semiquantitative MR bone erosion score of the hand and quantitative value for power Doppler signal in the finger joint were both responsive and predictive of structural damage progression at 1 year.
OBJECTIVES: To compare quantitative magnetic resonance imaging (MRI) and power Doppler ultrasonography (PDUS) with conventional measures of disease activity in rheumatoid arthritis (RA) patients treated with the anti-interleukin 6 (anti-IL 6) receptor antibody tocilizumab in terms of responsiveness at a few months to disease activity and ability to predict structural damage at 1 year. METHODS: A cohort of patients with RA (n = 29) was evaluated clinically including disease activity score 28 (DAS28) and by semiquantitative (SQ-) and quantitative (Q-) PDUS (bilateral metacarpophalangeal joints) and MRI (one hand and wrist) at initiation of treatment with anti-IL 6 receptor antibody agents and after 2 and 5 months. Conventional radiography for both hands and wrists was performed at baseline and at 12 months. Responsiveness was assessed by standardized response means (SRM). Areas under the curve (AUC) for measures at baseline, 2 and 5 months were correlated with structural damage at 1 year. RESULTS: Among the laboratory and clinical parameters, DAS28-ESR was the most responsive with a large effect size of SRM. Structural damage progressions for radiography and MR erosion were correlated with AUC of MR bone erosion and Q-PDUS, respectively. CONCLUSIONS: In the evaluation of disease activity in RApatients in the first few months after starting anti-IL 6 receptor antibody tocilizumab treatment, the semiquantitative MR bone erosion score of the hand and quantitative value for power Doppler signal in the finger joint were both responsive and predictive of structural damage progression at 1 year.
Authors: M Østergaard; J Edmonds; F McQueen; C Peterfy; M Lassere; B Ejbjerg; P Bird; P Emery; H Genant; P Conaghan Journal: Ann Rheum Dis Date: 2005-02 Impact factor: 19.103
Authors: Stephen J Jarrett; Philip G Conaghan; Victor S Sloan; Philemon Papanastasiou; Christine-Elke Ortmann; Philip J O'Connor; Andrew J Grainger; Paul Emery Journal: Arthritis Rheum Date: 2006-05
Authors: J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell Journal: Rheumatology (Oxford) Date: 2003-02 Impact factor: 7.580
Authors: Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Veena K Ranganath; Ami Ben-Artzi; Erin Duffy; Jenny Brook; Mihaela Taylor; Soo Choi; Harold Paulus; David A Elashoff Journal: Rheumatology (Oxford) Date: 2015-08-27 Impact factor: 7.580
Authors: Oscar Epis; Emilio Filippucci; Andrea Delle Sedie; Anna De Matthaeis; Eleonora Bruschi Journal: Rheumatol Int Date: 2013-01-26 Impact factor: 2.631
Authors: Marco A Cimmino; Massimiliano Parodi; Francesca Barbieri; Stefano Bombardieri; Giuseppe Zampogna; Annamaria Iagnocco; Alberto Batticciotto; Luca Maria Sconfienza; Luigi Sinigaglia; Fabrizio De Benedetti; Fabiola Atzeni; Piercarlo Sarzi-Puttini Journal: Biologics Date: 2020-02-11